FNDC5 and myeloid sarcoma: Table 1 present the demographic and clinical characteristics of the patients and controls. Serum irisin and nesfatin-1 levels were significantly lower in MS patients (Z score: -3.82, p<0.001; Z score: -4.79, p<0.001, respectively) (Figure 1).